Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-fluselenamyl
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-fluselenamyl is a small molecule diagnostic radiopharmaceutical developed for positron emission tomography (PET) imaging of beta-amyloid plaques in the brain. It is labeled with fluorine-18 and designed to bind specifically to both diffuse and fibrillar amyloid-beta (Aβ) plaques, which are characteristic of Alzheimer's disease pathology. Unlike some existing tracers, 18F-fluselenamyl demonstrates high affinity and specificity for Aβ aggregates, including diffuse plaques that are present at prodromal stages of Alzheimer's disease. Preclinical studies have shown rapid brain penetration, favorable kinetics, and no significant pharmacological or toxicological effects in animal models. The agent is being evaluated for its safety profile and dosimetry in humans as a tool for early detection and monitoring of Alzheimer’s disease progression[2][3][5][6][8].
- Other names
- fluselenamyl[18F]-Fluselenamyl
02
Targets
Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on 18F-fluselenamyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-fluselenamyl.